Clinical trial
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus…
NCT00273871 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00273871 |
|---|---|
| Title | Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients |
| Official title | A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Rejection, Kidney Failure, Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Cyclosporin or tacrolimus |
| Enrollment | 190 |
| Start date | Jan 1, 2002 |
| Completion | Sep 1, 2006 |
| First posted | Jan 9, 2006 |
| Last update posted | Mar 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: